I can't put a link, so hear is an excerpt you can search for (this new MB format sucks, it is condensing my post):
"Par Pharmaceutical Begins Shipment of Generic Zegerid(R)
WOODCLIFF LAKE, N.J., July 1, 2010 /PRNewswire via COMTEX/ --
Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade. Omeprazole and sodium bicarbonate capsules are the generic version of Santarus' Zegerid(R). Annual U.S. sales of Zegerid capsules are approximately $195 million, according to IMS Health data. Par has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for these strengths of the product."
This was before Par eroded the pricing by entering the market.
Currently, SNTS is selling $8-10 million per quarter (Zegerid line).. If PAR were forced to stop selling, maybe SNTS would be able to at least double the current sales numbers initially (I would hope), and maybe raise prices at some point. This would be a great start if SNTS began as the exclusive marketer of Zegerid line again. $80-100 million annual sales initially is my guess. Any other thoughts and projections I would love to hear. I was guessing that the market may be currently split by the two generics (SNTS and PAR), but I couldn't find the actual PAR numbers in the latest quarter report.